Sponsors (2)
Official title: To amend the Federal Food, Drug, and Cosmetic Act to provide for reciprocal marketing approval of certain drugs, biological products, and devices that are authorized to be lawfully marketed abroad, and for other purposes.
Introduced February 26, 2025 by Charles Roy · Last progress February 26, 2025
The bill speeds patient and hospital access to products already authorized abroad and eases market entry for sponsors, at the trade-off of increased safety risk if foreign standards differ, added administrative costs, and potential regulatory uncertainty and federal oversight expenses.
Patients with unmet medical needs and hospitals can gain earlier access to drugs, biologics, and devices already authorized in listed foreign countries or the UK, shortening wait times for treatment options.
Manufacturers and sponsors—including smaller firms—get a faster, clearer route to the U.S. market for products already authorized abroad, reducing time-to-market and duplicative regulatory work.
The FDA can impose postmarket studies or Risk Evaluation and Mitigation Strategies (REMS), allowing patients earlier access while the agency retains tools to monitor and manage safety after approval.
Patients (including seniors) could be exposed to unsafe or ineffective products if foreign regulatory standards differ and reciprocal approvals let products onto the U.S. market prematurely.
The bill's Congressional disapproval process could create regulatory uncertainty and instability for sponsors and patients if approvals are reversed or delayed.
Taxpayers and federal budgets may face increased costs from additional FDA review workload, outreach, and ongoing reporting required by the reciprocal program.
Based on analysis of 2 sections of legislative text.
Creates a statutory pathway for certain drugs, biologics, and devices authorized abroad or in the U.K. to be deemed to have active U.S. approval if sponsors request it and criteria are met.
Creates a fast-track "reciprocal marketing approval" pathway that lets a drug, biologic, or medical device already authorized in specified foreign countries or the United Kingdom be treated as having an active U.S. application or clearance if the sponsor requests it and meets criteria. The Department of Health and Human Services must decide within 30 days, can deny for safety/effectiveness reasons, may require postmarket studies, will negotiate labeling, apply existing FDA fees and statutes, and must report denials monthly to Congress with a special expedited congressional disapproval process available.